ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Evaluation of Multiple Breast Cancer Polygenic Risk Score Panels in Women of Latin American Heritage.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
46 authors.
Xiaosong HuangDepartment of Public Health Sciences, University of California Davis, Davis, California.ORCID 0000-0003-0627-1509
Paul C LottGenome Center, University of California Davis, Davis, California.ORCID 0000-0002-1611-442X
Donglei HuDivision of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.ORCID 0000-0002-0351-001X
Valentina A ZavalaDepartment of Public Health Sciences, University of California Davis, Davis, California.ORCID 0000-0003-2040-1760
Zoeb N JamalGenome Center, University of California Davis, Davis, California.ORCID 0009-0007-3255-9676
Tatiana VidaurreInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0003-1995-4560
Sandro Casavilca-ZambranoInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0001-8406-739X
Jeannie Navarro VásquezInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0009-0000-0775-8832
Carlos A CastañedaInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0001-6200-0856
Guillermo ValenciaInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-4234-4448
Marco Galvez-NinoInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-1408-4474
Scott HuntsmanDivision of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.ORCID 0000-0002-5440-6191
Sixto E SanchezDepartamento Académico de Medicina Preventiva y Salud Pública, Universidad Nacional Mayor de San Marcos, Lima, Peru.ORCID 0000-0003-0354-0523
Michelle A WilliamsDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0001-5807-5281
Bizu GelayeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0001-7934-548X
Ana P Estrada-FlorezGenome Center, University of California Davis, Davis, California.ORCID 0000-0001-5480-693X
Guadalupe Polanco-EcheverryGenome Center, University of California Davis, Davis, California.ORCID 0000-0002-3373-628X
Magdalena EcheverryGrupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.ORCID 0000-0003-4919-0821
Mabel E Bohorquez-LozanoGrupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.ORCID 0000-0002-7679-5570
Javier TorresUIM en Enfermedades Infecciosas, UMAE Pediatria, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.ORCID 0000-0003-3945-4221
Miguel CruzUIM en Bioquimica, UMAE especialidades, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.ORCID 0000-0001-9985-6172
Weang-Kee HoSchool of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Selangor, Malaysia.ORCID 0000-0002-8269-7344
Esther M JohnDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-3259-8003
Christopher A HaimanDepartment of Population and Public Health Science, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-0097-9971
David V ContiDepartment of Population and Public Health Science, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-2941-7833
Fei ChenDepartment of Population and Public Health Science, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-1679-9932
Gabriela Torres-MejíaCenter for Population Health Research, National Institute of Public Health (INSP), Cuernavaca, Mexico.ORCID 0000-0003-4052-6392
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Oakland, California.ORCID 0000-0001-9136-1175
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California.ORCID 0000-0001-5053-0390
Elad ZivDivision of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.ORCID 0000-0002-2324-2884
Luis G Carvajal-CarmonaGenome Center, University of California Davis, Davis, California.ORCID 0000-0001-7129-2918
COLUMBUS Consortium
Laura FejermanDepartment of Public Health Sciences, University of California Davis, Davis, California.ORCID 0000-0003-3179-1151
Funding
Leveraging Prospective Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk ScoresU01CA261339 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fei Chen, David V Conti · 2021 to 2026
$5.2M
Latin America Genomics of Breast Cancer Risk Study (LAGENO-BCR)R01CA286650 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Julie Dutil, Laura Fejerman · 2024 to 2026
$2.5M
Biological implications of breast cancer protective variants in Latin Americanwomen with high Indigenous American ancestryR01CA204797 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEJERMAN, LAURA · 2016 to 2020
$1.9M
Her2 status of breast cancer in diverse populations: improving genetic prediction and understanding molecular correlatesR01CA273313 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Laura Fejerman · 2023 to 2026
$1.8M
UC Davis Multi-Disciplinary Cancer Research Training Program to Advance Precision Cancer Prevention and Care in Latin America.D43CA260869 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Luis Guillermo Carvajal Carmona, Laura Fejerman · 2022 to 2026
$1.2M
American Association for Cancer Research (AACR) Fellowship 21-40-69-ESTRNational Cancer Institute (NCI) R01-CA286650NCI NIH HHS D43 CA260869NCI NIH HHS R01 CA204797NCI NIH HHS R01 CA273313NCI NIH HHS R01 CA286650NCI NIH HHS U01 CA261339
6 · The paper itself
Abstract
backgroundA substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been identified mostly in individuals of European (EUR) and Asian ancestries, have been combined to construct a polygenic risk score (PRS) to predict breast cancer risk, but the prediction accuracy of existing PRSs in Hispanic/Latinx individuals (H/L) remain relatively low. We assessed the performance of several existing PRS panels with and without addition of H/L-specific variants among self-reported H/L women.
methodsPRS performance was evaluated using multivariable logistic regression and the area under the ROC curve.
resultsBoth EUR and Asian PRSs performed worse in H/L samples compared with original reports. The best EUR PRS performed better than the best Asian PRS in pooled H/L samples. EUR PRSs had decreased performance with increasing Indigenous American (IA) ancestry, while Asian PRSs had increased performance with increasing IA ancestry. The addition of two H/L SNPs increased performance for all PRSs, most notably in the samples with high IA ancestry, and did not impact the performance of PRSs in individuals with lower IA ancestry.
conclusionsA single PRS that incorporates risk variants relevant to the multiple ancestral components of individuals from Latin America, instead of a set of ancestry-specific panels, could be used in clinical practice. IMPACT: The results highlight the importance of population-specific discovery and suggest a straightforward approach to integrate ancestry-specific variants into PRSs for clinical application.
Indexed as
Breast NeoplasmsGenetic Predisposition to DiseaseHispanic or LatinoMultifactorial InheritanceAdultFemaleGenetic Risk ScoreHumansLatin AmericaMiddle AgedPolymorphism, Single NucleotideRisk AssessmentRisk Factors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Evaluation of Multiple Breast Cancer Polygenic Risk Score Panels in Women of Latin American Heritage. · full record | OpenQuestion